Clinical

Dataset Information

0

Multicenter Randomized Controlled Trial of Combination Antiemetic Therapy with Aprepitant/Fosaprepitant in Patients with Colorectal Cancer Receiving Oxaliplatin-based chemotherapy


ABSTRACT: Interventions: For aprepitant therapy Aprepitant; 125 mg PO on day 1, 80 mg PO on days 2 to 3 5HT3-receptor antagonist; IV administration on day 1 Dexamethasone; 6.6 mg IV on day 1, 4 mg PO on days 2 to 3 For fosaprepitant therapy Fosaprepitant; 150 mg IV on day 1 5HT3-receptor antagonist; IV administration on day 1 Dexamethasone; 6.6 mg IV on day 1, 4 mg PO on day 2 and 8mg PO on day 3 5HT3-receptor antagonist; IV administration on day 1 Dexamethasone; 9.9 mg IV on day 1, 8 mg PO on days 2 to 3 Primary outcome(s): Proportion of patients with ‘No emesis" Study Design: Parallel Randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2620869 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2622198 | ecrin-mdr-crc
| 2647713 | ecrin-mdr-crc
| 2105952 | ecrin-mdr-crc
| 2225674 | ecrin-mdr-crc
2023-02-01 | GSE224046 | GEO
| 2640480 | ecrin-mdr-crc
| 2013397 | ecrin-mdr-crc
| 2629132 | ecrin-mdr-crc
2020-03-01 | GSE128167 | GEO
| 2615810 | ecrin-mdr-crc